Overview
Empirico uses human genetics and large biological data to discover and develop new medicines, focusing on target discovery and drug development through collaborations. Its Precision Insights Platform analyzes genetic and health data from millions, with curated data, custom models, and proprietary algorithms to generate and rank high-confidence therapeutic hypotheses. It validates these hypotheses through experiments and partnerships (such as with AbCellera) to understand how genetic variation affects disease risk and how a therapy could mimic or block that mechanism. By combining vast datasets with genetics-driven validation and external collaborations, Empirico aims to increase the success rate of drug discovery and translate genetic insights into new medicines.
Work here?Claim your company
Simplify's take
What believers are saying
- GSK licensed EMP-012 on October 28, 2025 for $85 million upfront.
- The deal validates Empirico's target discovery and siRNA platform with a global pharma.
- AbCellera expanded its multi-target collaboration with Empirico in May 2022.
What critics are saying
- GSK now holds EMP-012's worldwide rights, stripping Empirico's best near-term value driver.
- Empirico depends on partnerships; one failed program can stall financing and hiring.
- If genetics-driven targets disappoint clinically, Empirico's platform loses its core differentiation.
What makes Empirico unique
- Empirico's human genetics platform ties disease targets to protective variants, boosting biological validity.
- Its siRCH and Precision Insights platforms span discovery through phase I translation.
- La Jolla discovery plus Madison validation keeps genetics, chemistry, and models tightly integrated.
Help us improve and share your feedback! Did you find this helpful?